• Explore /
  • Poster
  • / Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT).

Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT).

Abstract Poster

Authors

null

Jorge Riera-Knorrenschild

Universitätsklinikum Giessen und Marburg, Marburg, Germany

Jorge Riera-Knorrenschild , Hans-Joachim Schmoll , Dirk Arnold , Hendrik Kroening , Frank Mayer , Dieter Nitsche , Reinhard Ziebermayr , Werner Scheithauer , Johannes Andel , Christian Meisel , Manuel Schmidt , Burghardt Wittig

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01208194

Citation

J Clin Oncol 31, 2013 (suppl; abstr 3643)

DOI

10.1200/jco.2013.31.15_suppl.3643

Abstract #

3643

Poster Bd #

14E

Abstract Disclosures

Similar Posters

First Author: Jorge Riera-Knorrenschild

First Author: Johanna C. Bendell

First Author: Thomas Hoehler

First Author: Sotaro Sadahiro